Top Story Today
An Epilepsy Drug Nobody Expected Just Pole-Vaulted Over Every Benchmark
Xenon Pharmaceuticals' azetukalner posted a 42.8% placebo-adjusted median percent reduction in seizure frequency, obliterating analyst expectations of 25-30%. More than half of patients on the top dose cut their seizures by at least 50%, and shares surged roughly 47% in a single session. The drug targets Kv7 potassium channels, a completely novel mechanism that amplifies the brain's natural braking system rather than dampening excitatory signals. Xenon plans to file for FDA approval in Q3 2026, with a potential launch in late 2027.
Why it matters: For the 30% of epilepsy patients who don't respond to current medications, azetukalner represents the first genuinely new mechanism of action in years, and its record-setting efficacy could reshape treatment guidelines for focal onset seizures.
Read more →Phase 3 Wins Keep Rolling
Vertex's $4.9B Kidney Bet Is Looking Like a Bargain
Vertex's povetacicept delivered a 49.8% reduction in urine protein in IgA nephropathy patients, validating the company's biggest-ever acquisition. Shares spiked after hours. The company is already filing a rolling FDA submission and holds a priority review voucher that could put approval on track for the second half of 2026, giving Vertex its first major revenue stream outside cystic fibrosis.
Read more →BMS Proves Its Revlimid Successor Isn't Just a Science Project
Mezigdomide, BMS's next-generation CELMoD drug, hit its primary progression-free survival endpoint in relapsed multiple myeloma. The win validates an entire new drug class designed to overcome resistance to older therapies like lenalidomide. Full data are coming at a medical conference, and a head-to-head trial against BMS's own older drug will be the real proving ground.
Read more →Takeda's Psoriasis Pill Just Posted Biologic-Level Results
Over 50% of patients on zasocitinib hit PASI 90 (90% skin clearance) by week 16, numbers typically reserved for injectable biologics. The oral TYK2 inhibitor swept all 44 ranked secondary endpoints and crushed existing oral competitor Otezla. With peak sales estimates of $3 to $6 billion, Takeda's $4 billion upfront acquisition of Nimbus Therapeutics' TYK2 inhibitor program (worth up to $6 billion total) is starting to look like a steal.
Read more →Deals and Strategy
GSK Sold Its Itch Drug Two Weeks Before the FDA Finish Line
GSK handed worldwide rights to linerixibat, a treatment for severe itching in rare liver disease, to Italian pharma company Alfasigma for $300 million upfront. The FDA decision date is March 24; that's days away. The deal (worth up to $690 million total) reflects GSK's push to shed niche assets and Alfasigma's ambition to build a liver disease franchise.
Read more →